Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Berger, Ariel ^a   Edelsberg, John ^a   Sanders, Kafi N ^b   Alvir, Jose Ma J ^b   Mychaskiw, Marko A ^b   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b PFIZER INC   (United States)

Author keywords

Antipsychotic agents; Bipolar disorder; Healthcare costs; Schizophrenia; Utilization

Indexed keywords

AMFEBUTAMONE; AMOBARBITAL; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; FLUPENTIXOL; HALOPERIDOL; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE; ZOLPIDEM;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD; MENTAL PATIENT; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; COMORBIDITY; DATA BASE; MEDICATION COMPLIANCE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DATABASES, FACTUAL; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; PATIENT DISCHARGE; PIPERAZINES; QUINOLONES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; THIAZOLES;

EID: 84864457369     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-99     Document Type: Article

References (32)

1. Department of Health and Human Services or National Institutes of Health Schizophrenia 2009, National Institute of Mental Health (US), Bethesda (MD), http://www.nimh.nih.gov/health/publications/schizophrenia/schizophrenia-booket-2009.pdf., Department of Health and Human Services or National Institutes of Health.
2. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004, 363:2063-2072. 10.1016/S0140-6736(04)16458-1, 15207959.
3. Office of the Surgeon General In Mental Health: A Report of the Surgeon General 1999, National Institute of Mental Health, Rockville (MD), Goldman HH, Rye P, Sirovatka P, http://www.surgeongeneral.gov/library/mentalhealth/home.html., Office of the Surgeon General.
4. Gerlach J, Larsen EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psych Scand 1999, 394:113-117.
5. DeQuardo JR, Tandon R. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?. J Psych Res 1998, 32:229-242.
6. Kane JM. Treatment of schizophrenia. Schiz Bull 1987, 13:133-156.
7. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schiz Res 2004, 66:51-77.
8. The Medical Letter, Inc Treatment guidelines from the medical letter. Drugs for psychiatric disorders. Treat Guide Med Lett 2006, 4:35-46. The Medical Letter, Inc.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, , et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 2005, 353:1209-1223. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
10. Chen L, McCombs JS, Park J. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia. Value Health 2008, 11:34-43. 10.1111/j.1524-4733.2007.00212.x, 18237358.
11. Garver D, Lazarus A, Rajagopalan K, Lamerato L, Katz LM, Stern LS, Dolgitser M, Doyle JJ. Racial differences in medication switching and concomitant prescriptions in the treatment of bipolar disorder. Psychiatric Services 2006, 57:666-672. 10.1176/appi.ps.57.5.666, 16675761.
12. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psych Serv 2004, 55:886-891.
13. Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: A retrospective database study. Clin Ther 2006, 28:1912-1921. 10.1016/j.clinthera.2006.11.002, 17213012.
14. Breen R, Thornhil JT. Noncompliance with medication for psychiatric disorders: Reasons and remedies. CNS Drugs 1998, 9:457-471.
15. Battaglia J. Compliance with treatment in schizophrenia November 2001, MedscapeCME, http://cme.medscape.com/viewarticle/418612..
16. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995, 46:1049-1054.
17. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886-891. 10.1176/appi.ps.55.8.886, 15292538.
18. Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: A retrospective study. Ann Gen Psych 2009, 8:7. doi.
19. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE, Hsiao JK, Lieberman JA. What CATIE found: Results from the schizophrenia trial. Psych Serv 2008, 59:500-506.
20. Ascher-Svanum H, Zhu B, Faries DE, Salkerver D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2. 10.1186/1471-244X-10-2, 2817695, 20059765.
21. Becker MA, Young MS, Ochshorn E, Diamond RJ. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Admin Policy Mental Health 2007, 34:307-314.
22. Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum LE. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy-results from a managed care administrative claims database. J Man Care Pharm 2005, 11:145-150.
23. Eaddy MT, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005, 27:263-272. 10.1016/j.clinthera.2005.02.003, 15811492.
24. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psych 2004, 161:692-699.
25. Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health System Pharm 2009, 66:358-365.
26. Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: Results from the European Mania in Bipolar Longitudinal Evaluation of Medicine (EMBLEM) study. Psych Res 2011, 190:110-114.
27. Joyce AT, Harrison DJ, Loebel AD, Ollendorf DA. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Man Care 2005, 11:S254-S261.
28. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: Associations with resource use and cost. Brit J Psych 2004, 184:509-516.
29. Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Dis 2002, 71:131-139. 10.1016/S0165-0327(01)00394-9, 12167509.
30. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schiz Bull 2008, 34:173-180.
31. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007, 23:2305-2312. 10.1185/030079907X226050, 17697454.
32. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psych Serv 2003, 54:508-516.